New FDA Approval: Deucravacitinib (Sotyktu), a First-In-Class Oral, Allosteric Tyrosine Kinase 2 Inhibitor

In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug.

This premium deep dive into deucravacitinib includes:

  • the industry context
  • the clinical data
  • the target rationale
  • the mechanism of action
  • the drug’s origins
deucravacitinib (Sotyktu), deuterated TYK2 inhibitor, Newly approved for patients with plaque psoriasis, Deuteromethylamide suppresses N-demethylation via deuterium kinetic isotope effect, High selectivity for TYK2 over JAK1, JAK2, and JAK3

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from

…and hundreds more!